Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapy

Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapy - Effect of Ipragliflozin on combination with insulin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014968

Enrollment

Registered

2014-09-15

Start date

2014-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Ipragliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases more than BMI22

Exclusion criteria

Exclusion criteria: Contraindiction for Ipragliflozin Patients who may have been pregnant or pregnant women Patients who are considered low-nutrition and dehydration

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Secondary

Measure	Time frame
fasting plasma glucose sCPR IRI LDLc HDLc TG urine protein urine keton body weight insulin dose hypoglycemia	—

Countries

Japan

Contacts

Public ContactShinichi Tamaru

Tokyo Medical University Hospital Division of Diabetes,Metabolism and Endocrinology

16000-all.tamaru@kpe.biglobe.ne.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026